Legal Representation
Attorney
Janet P. Peyton
USPTO Deadlines
Next Deadline
1741 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-04-30)
Due Date
April 30, 2030
Grace Period Ends
October 30, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
20 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Apr 30, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Apr 30, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Feb 13, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Feb 13, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jan 24, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jan 11, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 11, 2024 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Jan 11, 2024 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jan 11, 2024 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jan 11, 2024 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Dec 26, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Dec 26, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Dec 26, 2023 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Jul 31, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| May 12, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| May 12, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| May 12, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 5, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 24, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Oct 11, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of angioedema; Pharmaceutical preparations for the treatment of hereditary angioedema; Pharmaceutical preparations for the treatment of bradykinin mediated inflammatory disorders; Pharmaceutical preparations for the treatment of diseases and disorders mediated by the contact activation system; Pharmaceutical preparations for the treatment of plasma kallikrein or factor XIIa mediated diseases or disorders; Pharmaceutical preparations for containing sebetralstat; Pharmaceutical preparations for containing feniralstat(Based on 44(d) Priority Application) Pharmaceutical preparations for the treatment of angioedema; Pharmaceutical preparations for the treatment of hereditary angioedema; Pharmaceutical preparations for the treatment of bradykinin mediated inflammatory disorders; Pharmaceutical preparations for the treatment of diseases and disorders mediated by the contact activation system; Pharmaceutical preparations for the treatment of plasma kallikrein or factor XIIa mediated diseases or disorders; Pharmaceutical preparations for containing sebetralstat for the treatment of angioedema, hereditary angioedema, bradykinin mediated inflammatory disorders, plasma kallikrein or factor XIIa mediated diseases or disorders, or diseases and disorders mediated by the contact activation system
Classification
International Classes
005